Creon 40,000 for Treatment of PEI (Pancreatic Exocrine Insufficiency) Due to Chronic Pancreatitis
Launched by ABBOTT PRODUCTS · Jun 26, 2008
Trial Information
Current as of June 25, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- • Inclusion Criteria
- • Pancreatic exocrine insufficiency has to be proven (in medical history) by a pancreatic function test
- • Chronic pancreatitis has to be proven (in medical history) by CT, ERCP, plain film with pancreatic calcifications, ultrasonography (calcifications,duct dilatation) and /or histology
- • Females must be non-lactating and either be of non-childbearing potential or if of childbearing potential, agree to practice effective barrier contraceptive methods, use an intrauterine device (IUD) or use birth control pills or equivalent injectable contraceptive. The subject must have been practicing the selected method of birth control for at least 3 months prior to Visit 1 (Day -14).
- • Subjects with a pathological stool fat during run in period (\> 10g/24 h)
- • Exclusion Criteria
- • Ileus or acute abdomen
- • Any type of malignancy involving the digestive tract in the last 5 years
- • Presence of pseudo pancreatic cysts \>= 4 cm
- • Current excessive intake of alcohol or drug abuse
- • Hypersensitivity vs porcine proteins / pancreatin
About Abbott Products
Abbott Products is a global healthcare company dedicated to advancing medical science and improving patient outcomes through innovative products and solutions. With a strong focus on research and development, Abbott engages in clinical trials to evaluate the safety and efficacy of its diverse portfolio, which includes diagnostics, medical devices, nutrition, and pharmaceuticals. Committed to upholding the highest ethical standards, Abbott collaborates with healthcare professionals and regulatory bodies to ensure rigorous study protocols and compliance, ultimately contributing to the advancement of healthcare worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bangalore, , India
Bhopal, , India
Chennai, , India
Cochin, , India
Hyderabad, , India
Jaipur, , India
Kolkatta, , India
Mumbai, , India
Pune, , India
Pune, , India
Trivandrum, , India
Patients applied
Trial Officials
Guenter Krause, MD
Study Director
Abbott Products
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials